Negative in Ames, in vitro CHO chromosomal aberration and rat micronucleus assays
“Fedratinib was not mutagenic in a bacterial reverse mutation (Ames) assay, or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or in vivo in a micronucleus test in rats.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Carcinogenicity
6-month Tg.rasH2 mouse: no drug-related neoplasms; no 2-year rat study
“In a 6-month carcinogenicity study in transgenic Tg.RasH2 mice, there were no neoplasms that were attributed to treatment with fedratinib. No 2-year carcinogenicity study in rats was performed.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat fertility: no remarkable effects; rat EFD: maternal toxicity at mid and high doses
“There were no remarkable fedratinib‐related effects in the FEED study. In the EFD study in rats, fedratinib was maternally toxic at the middle and high dose levels with lower gestational body weight gain and decreased gravid uterine weights.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗
Safety pharmacology
No significant cardiovascular or respiratory effects in dogs; no clear CNS effects in rats (non-dose-dependent miosis)
“In vivo, fedratinib was not associated with toxicologically significant effects on cardiovascular or respiratory parameters in dogs. There were no clear drug‐related CNS effects in rats; eye miosis and lack of pupillary responses were observed but were non‐dose‐dependent.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Genotox: Ames
Negative
“Fedratinib was not mutagenic in a bacterial reverse mutation (Ames) assay, or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or in vivo in a micronucleus test in rats.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Genotox: in vitro mammalian
Negative: chromosomal aberration assay in CHO cells
“Fedratinib was not mutagenic in a bacterial reverse mutation (Ames) assay, or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or in vivo in a micronucleus test in rats.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Genotox: in vivo
Negative: rat micronucleus test
“Fedratinib was not mutagenic in a bacterial reverse mutation (Ames) assay, or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or in vivo in a micronucleus test in rats.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Carcinogenicity model
6-month Tg rasH2 mouse (negative); 2-year rat not performed
“In a 6-month carcinogenicity study in transgenic Tg.RasH2 mice, there were no neoplasms that were attributed to treatment with fedratinib. No 2-year carcinogenicity study in rats was performed.”
6-month Tg rasH2 mouse completed before the marketing application; 2-year rat not performed (waived)
“In a 6-month carcinogenicity study in transgenic Tg.RasH2 mice, there were no neoplasms that were attributed to treatment with fedratinib. No 2-year carcinogenicity study in rats was performed.”
Unbound human Cmax (~0.35 µM) below the hERG IC50; dedicated clinical QT study showed no effect
“Therefore, the unbound Cmax in humans of around 0.35 µM is below the IC50 for hERG channel inhibition. Further, a dedicated clinical QT study was performed which showed no effect on the cardiac action potential.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative